Vascular cognitive impairment: Dementia biology and translational animal models

Current Opinion in Investigational Drugs

Volumn 10, Issue 7, 2009, Pages 624-637

  Barone, Frank C ^a,b   Rosenbaum, Daniel M ^a,b   Zhou, Jin ^a   Crystal, Howard ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b SUNY Downstate Medical Center   (United States)

Author keywords

Alzheimer's disease; Cerebrovascular disease; Experimental model; Neurovascular unit; Vascular dementia; Vascular risk factors

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; AMYLOID BETA PROTEIN; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; CALCIUM CHANNEL BLOCKING AGENT; CHOLINESTERASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DONEPEZIL; ENALAPRIL MALEATE PLUS NITRENDIPINE; GALANTAMINE; HYDROCHLOROTHIAZIDE; IMMUNOMODULATING AGENT; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; PERINDOPRIL; RESERPINE; RIVASTIGMINE;

ALZHEIMER DISEASE; BRAIN HEMORRHAGE; BRAIN INJURY; BRAIN ISCHEMIA; BRAIN PERFUSION; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; COGNITIVE DEFECT; DEMENTIA; DISEASE COURSE; HUMAN; HYPERTENSION; NONHUMAN; PREVALENCE; REVIEW; RISK FACTOR;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; CEREBROVASCULAR CIRCULATION; DEMENTIA, VASCULAR; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; HUMANS; MODELS, NEUROLOGICAL; NEURONS; RISK FACTORS;

EID: 68149147412     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (203)

1. Tomlinson BE, Blessed G, Roth M: Observations on the brains of demented old people. J Neurol Sci. (1970) 11(3):205-242.
2. Hachinski VC, Lassen NA, Marshall J: Multi-infarct dementia. A cause of mental deterioration in the elderly. Lancet. (1974) 2(7874):207-210.
3. Jellinger, KA, Attems J: Neuropathological evaluation of mixed dementia. J Neurol Sci. (2007) 257(1-2):80-87.
4. Crystal HA, Dickson D, Davies P, Masur D, Grober E, Lipton RB: The relative frequency of "dementia of unknown etiology" increases with age and is nearly 50% in nonagenarians. Arch Neurol. (2000) 57(5):713-719.
5. Hachinski V: Vascular dementia: A radical redefinition. Dementi. (1994) 5(3-4):130-132.
6. Bowler JV, Steenhuis R, Hachinski V: Conceptual background to vascular cognitive impairment. Alzheimer Dis Assoc Disord. (1999) 13(Suppl 3):S30-S37.
7. Bowler JV: Modern concept of vascular cognitive impairment. Br Med Bul. (2007) 83(1):291-305.
8. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E: Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol. (1999) 56(3):303-308.
9. Petersen RC: Mild cognitive impairment: Transition between aging and Alzheimer's disease. Neurology. (2000) 15(3):93-101.
10. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B: Current concepts in mild cognitive impairment. Arch Neurol. (2001) 58(12):1985-1992.
11. Lehrner J, Gufler R, Guttmann G, Maly J, Gleiss A, Auff E, Dal-Bianco P: Annual conversion to Alzheimer disease among patients with memory complaints attending an outpatient memory clinic: The influence of amnestic mild cognitive impairment and the predictive value of neuropsychological testing. Wien Klin Wochensch. (2005) 117(18):629-635.
12. O'Brien JT: Vascular cognitive impairment. Am J Geriatr Psychiatry. (2006) 14(9):724-733.
13. Kalaria RN, Maestre GE, Arizaga R, Friedland RP, Galasko D, Hall K, Luchsinger JA, Ogunniyi A, Perry EK, Potocnik F, Prince M et al. Alzheimer's disease and vascular dementia in developing countries: Prevalence, management, and risk factors. Lancett Neurol. (2008) 7(9):812-826.
14. Bowler JV, Hachinski V (Eds): Vascular Cognitive Impairment. Preventable Dementi. Oxford University Press, Oxford, UK (2003).
15. Di Legge S, Hachinski V: Prospects for prevention and treatment of vascular cognitive impairment. Curr Opin Investig Drug. (2003) 4(9):1082-1087. An excellent review of VCI that focuses on the importance of preventing VCI progression by intervening early, prior to cognitive change. The future use of imaging biomarkers and risk factor control is emphasized, as is the coupling with neuropsychological, genetic and pathological features, to establish diagnostic criteria for early VCI.
16. Graham JE, Rockwood K, Beattie BL, Eastwood R, Gauthier S, Tuokko H, McDowell I: Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancett. (1997) 349(9068):1793-1796.
17. Moorhouse P, Rockwood K: Vascular cognitive impairment: Current concepts and clinical developments. Lancett Neurol. (2008) 7(3):246-255.
18. Iadecola C, Gorelick PB: Converging pathogenic mechanisms in vascular and neurodegenerative dementia. Stroke. (2003) 34(2):335-337. Outstanding position piece emphasizing the synergistic interaction between major causative factors in AD (amyloid-β peptid. Aβ) and VCI (vascular insufficiency). Aβ, in addition to its well known toxic effects on brain cells, induces vascular insufficiency that can exacerbate the deleterious effects of this compound. In addition, vascular insufficiency in VCI can increase Aβ and exacerbate its effects. Thus the effects of Aβ in vascular insufficiency, cerebral ischemia and AD can result in increased cognitive impairment.
19. Gorelick PB, Bowler JV: Advances in vascular cognitive impairment 2007. Stroke. (2008) 39(2):279-282.
20. Erkinjuntti T: Vascular cognitive deterioration and stroke. Cerebrovasc Dis. (2007) 24(Suppl 1):189-194. Describes the effects of vascular disease on cognition, and the interactions between vascular etiologies, risk factors and cellular changes within the brain. Includes a discussion of vascular risk factors and stroke as independent factors for the clinical presentation of AD (eg, CVD and strokes, infarcts, and white-matter lesions may trigger and modify the progression of AD).
21. Hachinski V, Iadecola C, Petersen RC, Breteler MM, Nyenhuis DL, Black SE, Powers WJ, DeCarli C, Merino JG, Kalaria RN, Vinters HV et al. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke. (2006) 37(9):2220-2241. Description of a meeting of researchers to discuss clinical diagnosis, epidemiology, neuropsychology, brain imaging, neuropathology, experimental models, biomarkers, genetics and clinical trials to recommend minimum, common, clinical and research standards for the description and study of VCI.
22. Masur DM, Sliwinski M, Lipton RB, Blau AD, Crystal HA: Neuropsychological prediction of dementia and the absence of dementia in healthy elderly persons. Neurology. (1994) 44(8):1427-1432.
23. Dickson DW, Davies P, Bevona C, Van Hoeven KH, Factor SM, Grober E, Aronson MK, Crystal HA: Hippocampal sclerosis: A common pathological feature of dementia in very old (> or = 80 years of age) humans. Acta Neuropathol. (1994) 88(3):212-221.
24. McKeith IG, Ballard CG, Perry RH, Ince PG, O'Brien JT, Neill D, Lowery K, Jaros E, Barber R, Thompson P, Swann A et al. Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology. (2000) 54(5):1050-1058.
25. Manolio TA, Olson J, Longstreth WT: Hypertension and cognitive function: Pathophysiologic effects of hypertension on the brain. Curr Hypertens Res. (2003) 5(3):255-261.
26. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A: Midlife vascular risk factors and Alzheimer's disease in later life: Longitudinal, population based study. Br Med. (2001) 322(7300):1447-1451.
27. Petrovitch H, White LR, Izmirilian G, Ross GW, Havlik RJ, Markesbery W, Nelson J, Davis DG, Hardman J, Foley DJ, Launer LJ: Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: The HAAS. Honolulu-Asia Aging Study. Neurobiol Aging. (2000) 21(1):57-62.
28. Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR, Havlik RJ: Midlife blood pressure and dementia: The Honolulu-Asia Aging Study. Neurobiol Aging. (2000) 21(1):49-55.
29. Tzourio C: Vascular factors and cognition: Toward a prevention of dementia?J Hyperten. (2003) 21(Suppl 5):S15-S19.
30. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, Persson G, Oden A, Svanborg A: 15-Year longitudinal study of blood pressure and dementia. Lancett. (1996) 347(9009):1141-1145.
31. Manolio TA, Olson J, Longstreth WT: Hypertension and cognitive function: Pathophysiologic effects of hypertension on the brain. Curr Hypertens Res. (2003) 5(3):255-261.
32. Madero M, Gul A, Sarnak MJ: Cognitive function in chronic kidney disease. Semin Dia. (2008) 21(1):29-37.
33. Kloppenborg RP, van den Berg E, Kappelle LJ, Biessels GJ:Diabetes and other vascular risk factors for dementia: Which factor matters most? A systematic review. Eur J Pharmacol. (2008) 585(1):97-108.
34. Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, O'Brien PC, Palumbo PJ: Risk of dementia among persons with diabetes mellitus: A population-based cohort study. Am J Epidemio. (1997) 145(4):301-308.
35. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM:Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology. (1999) 53(9):1937-1942.
36. MacKnight C, Rockwood K, Awalt E, McDowell I: Diabetes mellitus and the risk of dementia, Alzheimer's disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dement Geriatr Cogn Disord. (2002) 14(2):77-83.
37. Roberts RO, Geda YE, Knopman DS, Christianson TJ, Pankratz VS, Boeve BF, Vella A, Rocca WA, Petersen RC:Association of duration and severity of diabetes mellitus with mild cognitive impairment. Arch Neurol. (2008) 65(8):1066-1073.
38. Luchsinger JA, Tang MX, Shea S, Mayeux R: Caloric intake and the risk of Alzheimer disease. Arch Neurol. (2002) 59(8): 1258-1263.
39. Cohen MB, Mather PJ: A review of the association between congestive heart failure and cognitive impairment. Am J Geriatr Cardio. (2007) 16(3):171-174.
40. Hofman A, Ott A, Breteler MM, Bots ML, Slooter AJ, van Harskamp F, van Duijn CN, Van Broeckhoven C, Grobbee DE: Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancett. (1997) 349(9046):151-154.
41. Ott A, Breteler MM, de Bruyne MC, van Harskamp F, Grobbee DE, Hofman A: Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke. (1997) 28(2):316-321.
42. Kilander L, Andren B, Nyman H, Lind L, Boberg M, Lithell H: Atrial fibrillation is an independent determinant of low cognitive function: A cross-sectional study in elderly men.Stroke. (1998) 29(9):1816-1820.
43. Tan ZS, Seshadri S, Beiser A, Wilson PW, Kiel DP, Tocco M, D'Agostino RB, Wolf PA: Plasma total cholesterol level as a risk factor for Alzheimer disease: The Framingham Study. Arch Intern Med. (2003) 163(9):1053-1057.
44. Lindsay J, Laurin D, Verreault R, Hebert R, Helliwell B, Hill GB, McDowell I: Risk factors for Alzheimer's disease: A prospective analysis from the Canadian Study of Health and Aging. Am J Epidemio. (2002) 156(5):445-453.
45. DeCarli C: The role of cerebrovascular disease in dementia. Neurology. (2003) 9(3):123-136.
46. Tatemichi TK, Paik M, Bagiella E, Desmond DW, Stern Y, Sano M, Hauser WA, Mayeux R: Risk of dementia after stroke in a hospitalized cohort: Results of a longitudinal study. Neurology. (1994) 44(10):1885-1891.
47. Censori B, Manara O, Agostinis C, Camerlingo M, Casto L, Galavotti B, Partziguian T, Servalli MC, Cesana B, Belloni G, Mamoli A: Dementia after first stroke. Stroke. (1996) 27(7):1205-1210.
48. Pohjasvaara T, Erkinjuntti T, Ylikoski R, Hietanen M, Vataja R, Kaste M: Clinical determinants of poststroke dementia. Stroke. (1998) 29(1):75-81.
49. Kokmen E, Whisnant JP, O'Fallon WM, Chu CP, Beard CM:Dementia after ischemic stroke: A population-based study in Rochester, Minnesota (1960-1984). Neurology. (1996) 46(1):154-159.
50. Henon H, Durieu I, Guerouaou D, Lebert F, Pasquier F, Leys D: Poststroke dementia: Incidence and relationship to prestrike cognitive decline. Neurology. (2001) 57(7):1216-1222.
51. Kalaria RN: Small vessel disease and Alzheimer's dementia:Pathological considerations. Cerebrovasc Dis. (2002) 13(Suppl 2):48-52.
52. Suter OC, Sunthorn T, Kraftsik R, Straubel J, Darekar P, Khalili K, Miklossy J: Cerebral hypoperfusion generates cortical watershed microinfarcts in Alzheimer disease. Stroke. (2002) 33(8):1986-1992.
53. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR: Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. J Am Med Asso. (1997) 277(10): 813-817.
54. Barba R, Castro MD, del Mar Morin M, Rodriguez-Romero R, Rodriguez-Garcia E, Canton R, Del Ser T: Prestroke dementia. Cerebrovasc Dis. (2001) 11(3):216-224.
55. Jellinger KA: The pathology of 'vascular dementia':A critical update. J Alzheimers Dis. (2008) 14(1):107-123.
56. De La Torre JC: Alzheimer's disease: How does it start?J Alzheimers Dis. (2002) 4(6):497-512.
57. Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, Lopresti BJ, Ziolko S, Bi W, Paljug WR, Debnath ML et al. Post-mortem correlates ofin vivoPiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain. (2008) 131(Pt 6):1630-1645.
58. Kalaria R: Similarities between Alzheimer's disease and vascular dementia. J Neurol Sci. (2002) 203-204:29-34.
59. de la Torre JC: Alzheimer disease as a vascular disorder: Nosological evidence. Stroke. (2002) 33(4):1152-1162.
60. Townsend KP, Obregon D, Quadros A, Patel N, Volmar Ch, Paris D, Mullan M: Proinflammatory and vasoactive effects of Aβ in the cerebrovasculature. Ann NY Acad Sci. (2002) 977:65-76.
61. Iadecola C: Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci. (2004) 5(5):347-360. A well constructed, intriguing review of cerebrovascular dysregulation as a feature not only of cerebrovascular pathologies, such as stroke, but also of neurodegenerative conditions, such as AD.
62. Zlokovic BV: Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci. (2005) 28(4):202-208. Emphasizes recent findings indicating that neurovascular dysfunction contributes to cognitive decline and neurodegeneration in AD (ie, unlike the traditional neuroncentric views).
63. de la Torre JC: Pathophysiology of neuronal energy crisis in Alzheimer's disease. Neurodegener Dis. (2008) 5(3-4):126-132.
64. Niwa K, Porter VA, Kazama K, Cornfield D, Carlson GA, Iadecola C: Ap-peptides enhance vasoconstriction in cerebral circulation. Am J Physiol Heart Circ Physiol. (2001) 281(6):H2417-H2424.
65. Niwa K, Younkin L, Ebeling C, Turner SK, Westaway D, Younkin S, Ashe KH, Carlson GA, Iadecola C: Aβ 1-40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation. Proc Natl Acad Sci USA. (2000) 97(17):9735-9740.
66. Niwa K, Kazama K, Younkin L, Younkin SG, Carlson GA, Iadecola C: Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. Am J Physiol Heart Circ Physiol. (2002) 283(1):H315-H323.
67. Borroni B, Akkawi N, Martini G, Colciaghi F, Prometti P, Rozzini L, Di Luca M, Lenzi GL, Romanelli G, Caimi L, Padovani A:Microvascular damage and platelet abnormalities in early Alzheimer's disease. J Neurol Sci. (2002) 203-204:189-193.
68. Park L, Anrather J, Zhou P, Frys K, Pitstick R, Younkin S, Carlson GA, Iadecola C: NADPH-oxidase-derived reactive oxygen species mediate the cerebrovascular dysfunction induced by the amyloidβ peptide. J Neurosci. (2005) 25(7):1769-1777.
69. Park L, Anrather J, Forster C, Kazama K, Carlson GA, Iadecola C: Aβ-induced vascular oxidative stress and attenuation of functional hyperemia in mouse somatosensory cortex. J Cereb Blood Flow Metab. (2004) 24(3):334-342.
70. Iadecola C: Cerebrovascular effects of amyloid-β peptides: Mechanisms and implications for Alzheimer's dementia. Cell Mol Neurobiol. (2003) 23(4-5):681-689. Outstanding review of data supporting the notion that vascular factors play a pathogenic role in the early stages of dementia in AD.
71. Barone FC, Kilgore KS: Role of inflammation and cellular stress in brain injury and central nervous system diseases. Clin Neurosci Res. (2006) 6(5):329-356.
72. Coma M, Guix FX, Ill-Raga G, Uribesalgo I, Alameda F, Valverde MA, Munoz FJ: Oxidative stress triggers the amyloidogenic pathway in human vascular smooth muscle cells. Neurobiol Aging. (2008) 29(7):969-980.
73. Haglund M, Kalaria R, Slade JY, Englund E: Differential deposition of amyloidβ peptides in cerebral amyloid angiopathy associated with Alzheimer's disease and vascular dementia. Acta Neuropathol. (2006) 111(5):430-435.
74. van Groen T, Puurunen K, Maki HM, Sivenius J, Jolkkonen J: Transformation of diffuseβ-amyloid precursor protein andβ-amyloid deposits to plaques in the thalamus after transient occlusion of the middle cerebral artery in rats. Stroke. (2005) 36(7):1551-1556.
75. Makinen S, van Groen T, Clarke J, Thornell A, Corbett D, Hiltunen M, Soininen H, Jolkkonen J: Coaccumulation of calcium andβ-amyloid in the thalamus after transient middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab. (2008) 28(2):263-268.
76. Kalaria RN, Bhatti SU, Lust WD, Perry G: The amyloid precursor protein in ischemic brain injury and chronic hypoperfusion. Ann NY Acad Sci. (1993) 695:190-193.
77. Nihashi T, Inao S, Kajita Y, Kawai T, Sugimoto T, Niwa M, Kabeya R, Hata N, Hayashi S, Yoshida J: Expression and distribution ofβ amyloid precursor protein andβ amyloid peptide in reactive astrocytes after transient middle cerebral artery occlusion. Acta Neurochir (Wien. (2001) 143(3):287-295.
78. Koistinaho M, Kettunen MI, Goldsteins G, Keinanen R, Salminen A, Ort M, Bures J, Liu D, Kauppinen RA, Higgins LS, Koistinaho J: β-amyloid precursor protein transgenic mice that harbor diffuse Aβ deposits but do not form plaques show increased ischemic vulnerability: Role of inflammation. Proc Natl Acad Sci USA. (2002) 99(3):1610-1615. Important study that follows up on data suggesting that brain ischemia contributes to the pathogenesis of AD. Increased vulnerability to focal brain ischemia was demonstrated in mice overexpressing human amyloid precursor protein and was associated with enhanced microglial activation and inflammation.
79. Zhang F, Eckman C, Younkin S, Hsiao KK, ladecola C: Increased susceptibility to ischemic brain damage in transgenic mice overexpressing the amyloid precursor protein. J Neurosci. (1997) 17(20):7655- 7661.
80. Price JM, Sutton ET, Hellerman A, Thomas T: β -Amyloid induces cerebrovascular endothelial dysfunction in the rat brain. Neurol Res. (1997) 19(5):534-538.
81. Rhodin JA, Thomas TN, Clark L, Garces A, Bryant M: In vivocerebrovascular actions of amyloidβ-peptides and the protective effect of conjugated estrogens. J Alzheimers Dis. (2003) 5(4):275-286.
82. Folin M, Baiguera S, Fioravanzo L, Conconi MT, Grandi C, Nussdorfer GG, Parnigotto PP: Caspase-8 activation and oxidative stress are involved in the cytotoxic effect ofβ-amyloid on rat brain microvascular cells. Int J Mol Med. (2006) 17(3):431-435.
83. Jung SS, Van Nostrand WE: Humanin rescues human cerebrovascular smooth muscle cells from Aβ-induced toxicity. J Neurochem. (2003) 84(2):266-272.
84. Koistinaho M, Koistinaho J: Interactions between Alzheimer's disease and cerebral ischemia- focus on inflammation. Brain Res Brain Res Rev. (2005) 48(2):240-250.
85. Iadecola C: Rescuing troubled vessels in Alzheimer disease. Nat Med. (2005) 11(9):923-924.
86. Roy S, Rauk A: Alzheimer's disease and the 'ABSENT' hypothesis: Mechanism for amyloidβ endothelial and neuronal toxicity. Med Hypotheses. (2005) 65(1):123-137.
87. Girouard H, Iadecola C: Neurovascular coupling in the normal brain and in hypertension, stroke, and Alzheimer disease. J Appl Physiol. (2006) 100(1):328-335.
88. del Zoppo GJ, Mabuchi T: Cerebral microvessel responses to focal ischemia. J Cereb Blood Flow Metab. (2003) 23(8):879-894.
89. Humpel C, Marksteiner J: Cerebrovascular damage as a cause for Alzheimer's disease. Curr Neurovasc Res. (2005) 2(4):341-347.
90. Khalil Z, LoGiudice D, Khodr B, Maruff P, Masters C: Impaired peripheral endothelial microvascular responsiveness in Alzheimer's disease. JAlzheimers Dis. (2007) 11(1):25-32.
91. Rosengarten B, Paulsen S, Molnar S, Kaschel R, Gallhofer B, Kaps M: Acetylcholine esterase inhibitor donepezil improves dynamic cerebrovascular regulation in Alzheimer patients. J Neurol. (2006) 253(1):58-64.
92. Rhodin JA, Thomas T: A vascular connection to Alzheimer's disease. Microcirculation. (2001) 8(4):207-220.
93. Vicenzini E, Ricciardi MC, Altieri M, Puccinelli F, Bonaffini N, Di Piero V, Lenzi GL: Cerebrovascular reactivity in degenerative and vascular dementia: A transcranial Doppler study. Eur Neurol. (2007) 58(2):84-89.
94. de la Torre JC: Vascular basis of Alzheimer's pathogenesis. Ann NY Acad Sci. (2002) 977:196-215.
95. Farkas E, Luiten PGM: Cerebral microvascular pathology in aging and Alzheimer's disease. Prog Neurobiol. (2001) 64(6):575-611.
96. Matsuda H: Cerebral blood flow and metabolic abnormalities in Alzheimer's disease. Ann Nucl Med. (2001) 15(2):85-92.
97. Borroni B, Anchisi D, Paghera B, Vicini B, Kerrouche N, Garibotto V, Terzi A, Vignolo LA, Di Luca M, Giubbini R, Padovani A et al. Combined 99mTc-ECD SPECT and neuropsychological studies in MCI for the assessment of conversion to AD. Neurobiol Aging. (2006) 27(1):24-31.
98. Hirao K, Ohnishi T, Hirata Y, Yamashita F, Mori T, Moriguchi Y, Matsuda H, Nemoto K, Imabayashi E, Yamada M, Iwamoto T et al. The prediction of rapid conversion to Alzheimer's disease in mild cognitive impairment using regional cerebral blood flow SPECT. NeuroImage. (2005) 28(4):1014-1021.
99. Wardlaw JM, Sandercock PA, Dennis MS, Starr J: Is breakdown of the blood-brain barrier responsible for lacunar stroke, leukoaraiosis, and dementia?Stroke. (2003) 34(3):806-812.
100. Lehmann M, Regland B, Blennow K, Gottfries CG: Vitamin B12-B6-folate treatment improves blood-brain barrier function in patients with hyperhomocysteinaemia and mild cognitive impairment. Dement Geriatr Cogn Disord. (2003) 16(3):145-150.
101. Esposito G, Giovacchini G, Liow JS, Bhattacharjee AK, Greenstein D, Schapiro M, Hallett M, Herscovitch P, Eckelman WC, Carson RE, Rapoport SI: Imaging neuroinflammation in Alzheimer's disease with radiolabeled arachidonic acid and PET. J Nucl Med. (2008) 49(9):1414-1421.
102. Aliev G, Smith MA, Seyidov D, Neal ML, Lamb BT, Nunomura A, Gasimov EK, Vinters HV, Perry G, LaManna JC, Friedland RP:The role of oxidative stress in the pathophysiology of cerebrovascular lesions in Alzheimer's disease. Brain Pathol. (2002) 12(1):21-35.
103. Fiala M, Liu QN, Sayre J, Pop V, Brahmandam V, Graves MC, Vinters HV:Cyclooxygenase-2-positive macrophages infiltrate the Alzheimer's disease brain and damage the blood-brain barrier. Eur J Clin Invest. (2002) 32(5):360-371.
104. Zhou H, Saidel GM, LaManna JC: Cerebral blood flow adaptation to chronic hypoxia. Adv Exp Med Biol. (2008) 614:371-377.
105. Ratan RR, Siddiq A, Smirnova N, Karpisheva K, Haskew-Layton R, McConoughey S, Langley B, Estevez A, Huerta PT, Volpe B, Roy S et al. Harnessing hypoxic adaptation to prevent, treat, and repair stroke. J Mol Med. (2007) 85(12):1331-1338.
106. Farkas E, Luiten PG, Bari F: Permanent, bilateral common carotid artery occlusion in the rat: A model for chronic cerebral hypoperfusion-related neurodegenerative diseases. Brain Res Rev. (2007) 54(1):162-180. A comprehensive review of the 2VO animal model as a tool to study VCI.
107. Claus JJ, Breteler MM, Hasan D, Krenning EP, Bots ML, Grobbee DE, Van Swieten JC, Van Harskamp F, Hofman A: Regional cerebral blood flow and cerebrovascular risk factors in the elderly population. Neurobiol Aging. (1998) 19(1):57-64.
108. Ohta H, Nishikawa H, Kimura H, Anayama H, Miyamoto M:Chronic cerebral hypoperfusion by permanent internal carotid ligation produces learning impairment without brain damage in rats. Neuroscience.. (1997) 79(4):1039-1050.
109. Otori T, Katsumata T, Muramatsu H, Kashiwagi F, Katayama Y, Terashi A: Long-term measurements of cerebral blood flow and metabolism in a rat chronic hypoperfusion model. Clin Exp Pharmacol Physiol. (2003) 30(4):266-272.
110. Ulrich PT, Kroppenstedt S, Heimann A, Kempski O: Laser-Doppler scanning of local cerebral blood flow and reserve capacity and testing of motor and memory functions in a chronic 2-vessel occlusion model in rats. Stroke. (1998) 29(11):2412-2420.
111. Tomimoto H, lhara M, Wakita H, Ohtani R, Lin JX, Akiguchi I, Kinoshita M, Shibasaki H: Chronic cerebral hypoperfusion induces white matter lesions and loss of oligodendroglia with DNA fragmentation in the rat. Acta Neuropathol. (2003) 106(6): 527-543.
112. Choy M, Ganesan V, Thomas DL, Thornton JS, Proctor E, King MD, van der Weerd L, Gadian DG, Lythgoe MF: The chronic vascular and haemodynamic response after permanent bilateral common carotid occlusion in newborn and adult rats. J Cereb Blood Flow Metab. (2006) 26(8):1066-1075.
113. Farkas E, Institdris A, Domoki F, Mihaly A, Luiten PGM, Bari F: Diazoxide and dimethyl sulphoxide prevent cerebral hypoperfusion-related learning dysfunction and brain damage after carotid artery occlusion. Brain Res. (2004) 1008(2):252-260.
114. Liu HX, Zhang JJ, Zheng P, Zhang Y: Altered expression of MAP-2, GAP-43, and synaptophysin in the hippocampus of rats with chronic cerebral hypoperfusion correlates with cognitive impairment. Brain Res Mol Brain Res. (2005) 139(1):169-177.
115. Shang Y, Cheng J, Oi J, Miao H: Scutellariaflavonoid reduced memory dysfunction and neuronal injury caused by permanent global ischemia in rats. Pharmacol Biochem Behav. (2005) 82(1):67-73.
116. Murakami Y, Ikenoya M, Matsumoto K, Li H, Watanabe H: Ameliorative effect of tacrine on spatial memory deficit in chronic two-vessel occluded rats is reversible and mediated by muscarinic M1 receptor stimulation. Behav Brain Res. (2000) 109(1):83-90.
117. Sopala M, Danysz W: Chronic cerebral hypoperfusion in the rat enhances age-related deficits in spatial memory. J Neural Transm. (2001) 108(12):1445-1456.
118. de Bortoli VC, Tangrossi Junior H, de Aguiar-Correa FM, Almeida Sde S, de Oliveira AM: Inhibitory avoidance memory retention in the elevated T-maze is impaired after perivascular manipulation of the common carotid arteries. Life Sci. (2005) 76(18):2103-2114.
119. Sarti C, Pantoni L, Bartolini L, Inzitari D: Persistent impairment of gait performances and working memory after bilateral common carotid artery occlusion in the adult Wistar rat. Behav Brain Res. (2002) 136(1):13-20.
120. De Jong GI, Farkas E, Stienstra CM, Plass JR, Keijser JN, de la Torre JC, Luiten PGM: Cerebral hypoperfusion yields capillary damage in hippocampus CA1 that correlates to spatial memory impairment. Neuroscience. (1999) 91(1):203-210.
121. Pappas BA, de la Torre JC, Davidson CM, Keyes MT, Fortin T: Chronic reduction of cerebral blood flow in the adult rat: Late-emerging CA1 cell loss and memory dysfunction. Brain Res. (1996) 708(1-2):50-58.
122. Ohtaki H, Fujimoto T, Sato T, Kishimoto K, Fujimoto M, Moriya M, Shioda S: Progressive expression of vascular endothelial growth factor (VEGF) and angiogenesis after chronic ischemic hypoperfusion in rat. Acta Neurochir Suppl. (2006) 96:283-287.
123. Schmidt-Kastner R, Aguirre-Chen C, Saul I, Yick L, Hamasaki D, Busto R, Ginsberg MD: Astrocytes react to oligemia in the forebrain induced by chronic bilateral common carotid artery occlusion in rats. Brain Res. (2005) 1052(1):28-39.
124. Liu J, Jin DZ, Xiao L, Zhu XZ: Paeoniflorin attenuates chronic cerebral hypoperfusion-induced learning dysfunction and brain damage in rats. Brain Res. (2006) 1089(1):162-170.
125. Friedrich P, Aszodi A: MAP2: A sensitive cross-linker and adjustable spacer in dendritic architecture. FEBS Lett. (1991) 295(1-3):5-9.
126. Dawson DA, Hallenbeck JM: Acute focal ischemia-induced alterations in MAP2 immunostaining: Description of temporal changes and utilization as a marker for volumetric assessment of acute brain injury. J Cereb Blood Flow Metab. (1996) 16(1):170-174.
127. Thiel G: Synapsin I, synapsin II, and synaptophysin: Marker proteins of synaptic vesicles. Brain Pathol. (1993) 3(1):87-95.
128. Abraham H, Lazar G: Early microglial reaction following mild forebrain ischemia induced by common carotid artery occlusion in rats. Brain Res. (2000) 862(1-2):63-73.
129. Gottfries CG, Blennow K, Karlsson I, Wallin A: The neurochemistry of vascular dementia. Dementia. (1994) 5(3-4):163-167.
130. Keverne JS, Low WC, Ziabreva I, Court JA, Oakley AE, Kalaria RN: Cholinergic neuronal deficits in CADASIL. Stroke. (2007) 38(1):188-191.
131. Grantham C, Geerts H: The rationale behind cholinergic drug treatment for dementia related to cerebrovascular disease. J Neurol Sci. (2002) 203-204:131-136.
132. Tohgi H, Abe T, Kimura M, Saheki M, Takahashi S: Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia. J Neural Transm. (1996) 103(10): 1211-1220.
133. Ni JW, Matsumoto K, Li HB, Murakami Y, Watanabe H: Neuronal damage and decrease of central acetylcholine level following permanent occlusion of bilateral common carotid arteries in rat. Brain Res. (1995) 673(2):290-296.
134. Kondo Y, Ogawa N, Asanuma M, Matsuura K, Nishibayashi K, Iwata E: Preventive effects of bifemelane hydrochloride on decreased levels of muscarinic acetylcholine receptor and its mRNA in a rat model of chronic cerebral hypoperfusion. Neurosci Res. (1996) 24(4):409-414.
135. Barber R, Scheltens P, Gholkar A, Ballard C, McKeith I, Ince P, Perry R, O'Brien J: White matter lesions on magnetic resonance imaging in dementia with Lewy bodies, Alzheimer's disease, vascular dementia, and normal aging. J Neurol Neurosurg Psychiatry. (1999) 67(1):66-72.
136. de Groot JC, de Leeuw FE, Oudkerk M, Hofman A, Jolles J, Breteler MM: Cerebral white matter lesions and depressive symptoms in elderly adults. Arch Gen Psychiatry. (2000) 57(11):1071-1076.
137. de Leeuw FE, de Groot JC, Achten E, Oudekerk M, Ramos LM, Heijboer R, Hofman A, Jolles J, van Gijn J, Breteler MM: Prevalence of cerebral white matter lesions in elderly people: A population based magnetic resonance imaging study. The Rotterdam Scan study. J Neurol Neurosurg Psychiatry. (2001) 70(1):9-14.
138. Hachinski VC, Potter P, Merskey H: Leuko-araiosis. Arch Neurol. (1987) 44(1):21-23.
139. Pantoni L, Leys D, Fazekas F, Longstreth WT Jr, Inzitari D, Wallin A, Filippi M, Scheltens P, Erkinjuntti T, Hachinski V: Role of white matter lesions in cognitive impairment of vascular origin. Alzheimer Dis Assoc Disord. (1999) 13(Suppl 3):S49-S54.
140. Farkas E, Donka G, de Vos RAI, Mihaly A, Bari F, Luiten PGM: Experimental cerebral hypoperfusion induces white matter injury and microglial activation in the rat brain. Acta Neuropathol. (2004) 108(1):57-64.
141. Roman GC: Brain hypoperfusion: A critical factor in vascular dementia. Neurol Res. (2004) 26(5):454-458.
142. Takizawa S, Fukuyama N, Hirabayashi H, Kohara S, Kazahari S, Shinohara Y, Nakazawa H: Quercetin, a natural flavonoid, attenuates vacuolar formation in the optic tract in rat chronic cerebral hypoperfusion model. Brain Res. (2003) 980(1):156-160.
143. Wakita H, Tomimoto H, Akiguchi I, Matsuo A, Lin JX, Ihara M, McGeer PL: Axonal damage and demyelination in the white matter after chronic cerebral hypoperfusion in the rat. Brain Res. (2002) 924(1):63-70.
144. Cho KO, La HO, Cho YJ, Sung KW, Kim SY: Minocycline attenuates white matter damage in a rat model of chronic cerebral hypoperfusion. J Neurosci Res. (2006) 83(2):285-291.
145. Lee JH, Park SY, Shin YW, Hong KW, Kim CD, Sung SM, Kim KY, Lee WS: Neuroprotection by cilostazol, a phosphodiesterase type 3 inhibitor, against apoptotic white matter changes in rat after chronic cerebral hypoperfusion. Brain Res. (2006) 1082(1):182-191.
146. Kobayashi K, Hayashi M, Nakano H, Fukutami Y, Sasaki K, Shimazaki M, Koshino Y: Apoptosis of astrocytes with enhanced lysosomal activity and oligodendrocytes in white matter lesions in Alzheimer's disease. Neuropathol Appl Neurobiol. 2002) 28(3):238-251.
147. Scheltens P, Barkhof F, Leys D, Wolters EC, Ravid R, Kamphorst W:Histopathologic correlates of white matter changes in MRI in Alzheimer's disease and normal aging. Neurology. (1995) 45(5):883-888.
148. Thomas AJ, Perry R, Barber R, Kalaria RN, O'Brien JT: Pathologies and pathological mechanisms for white matter hyperintensities in depression. Ann NY Acad Sci. (2002) 977:333-339.
149. Tomimoto H, Akiguchi I, Wakita H, Suenaga T, Nakamura S, Kimura J: Regressive changes of astroglia in white matter lesions in cerebrovascular disease and Alzheimer's disease patients. Acta Neuropathol. (1997) 94(2):146-152.
150. Wakita H, Ruetzler C, Illoh KO, Chen Y, Takanohashi A, Spatz M, Hallenbeck JM: Mucosal tolerization to E-selectin protects against memory dysfunction and white matter damage in a vascular cognitive impairment model. J Cereb Blood Flow Metab. (2008) 28(2):341-353. Excellent study using 2VO (cerebral vascular insufficiency model) to demonstrate the protective effects of mucosal tolerance to E-selectin on preserving cognition and reducing white matter injury.
151. Wakita H, Tomimoto H, Akiguchi I, Kimura J: Glial activation and white matter changes in the rat brain induced by chronic cerebral hypoperfusion: An immunohistochemical study. Acta Neuropathol. (1994) 87(5):484-492.
152. Suenaga T, Ohnishi K, Nishimura M, Nakamura S, Akiguchi I, Kimura J: Bundles of amyloid precursor protein-immunoreactive axons in human cerebrovascular white matter lesions. Acta Neuropathol. (1994) 87(5):450-455.
153. Takeda H, Spatz M, Ruetzler C, McCarron R, Becker K, Hallenbeck J: Induction of mucosal tolerance to E-selectin prevents ischemic and hemorrhagic stroke in spontaneously hypertensive genetically stroke-prone rats. Stroke. (2002) 33(9):2156-2163.
154. Chen Y, Ruetzler C, Pandipati S, Spatz M, McCarron RM, Becker K, Hallenbeck JM: Mucosal tolerance to E-selectin provides cell-mediated protection against ischemic brain injury. Proc Natl Acad Sci USA. (2003) 100(25):15107-15112.
155. Miller A, Lider O, Weiner HL: Antigen-driven bystander suppression after oral administration of antigens. J Exp Med. (1991) 174(4):791-798.
156. Yamamoto H, Schmidt-Kastner R, Hamasaki DI, Yamamoto H, Parel JM: Complex neurodegeneration in retina following moderate ischemia induced by bilateral common carotid artery occlusion in Wistar rats. Exp Eye Res. (2006) 82(5):767-779.
157. Davidson CM, Pappas BA, Stevens WD, Fortin T, Bennett SA: Chronic cerebral hypoperfusion: Loss of pupillary reflex, visual impairment and retinal neurodegeneration. Brain Res. (2000) 859(1):96-103.
158. Barnett NL, Osborne NN: Prolonged bilateral carotid artery occlusion induces electrophysiological and immunohistochemical changes to the rat retina without causing histological damage. Exp Eye Res. (1995) 61(1):83-90.
159. Okamoto K, Yamori Y, Nagaoka A: Establishment of the stroke-prone spontaneously hypertensive rat (SHR). Circ Res. (1974) 34-35(Suppl I):143-153.
160. Nagoaka A, Iwatsuka H, Sozuski Z, Okamoto K: Genetic predisposition to stroke in spontaneously hypertensive rats. Am J Physiol. (1976) 230(5):1354-1359.
161. Yanori Y, Horie R, Handa H, Sato M, Fukase M: Pathogenic similarity of strokes in stroke-prone spontaneously hypertensive rats and humans. Stroke. (1976) 7(1):46-53.
162. Akiguchi I, Horie R, Ohtaka M, Yamori Y, Kawai C: Symptomatological analysis of stroke in stroke-prone SHR. Jpn Heart. (1977) 18(4):547-548.
163. Fredriksson K, Kalimo H, Nordborg C, Johansson BB, Olsson Y: Nerve cell injury in the brain of stroke-prone spontaneously hypertensive rats. Acta Neuropathol. (1988) 76(3):227-237.
164. Iadecola C, Nedergaard M: Glial regulation of the cerebral microvasculature. Nat Neurosci. (2007) 10(11):1369-1376.
165. Ma XL, Gao F, Nelson AH, Lopez BL, Christopher TA, Yue TL, Barone FC: Oxidative inactivation of nitric oxide and endothelial dysfunction in stroke-prone spontaneous hypertensive rats. J Pharmacol Exp Ther. (2001) 298(3):879-885.
166. Barone FC, Nelson AH, Ohlstein EH, Willette RN, Sealey JE, Laragh JH, Campbell WG Jr, Feuerstein GZ: Chronic carvedilol reduces mortality and renal damage in hypertensive stroke-prone rats. J Pharmacol Exp Ther. (1996) 279(2):948-955.
167. Abrahamsen CT, Barone FC, Campbell WG Jr, Nelson AH, Contino LC, Pullen MA, Grygielko ET, Edwards RM, Laping NJ, Brooks DP: The angiotensin type 1 receptor antagonist, eprosartan, attenuates the progression of renal disease in spontaneously hypertensive stroke-prone rats with accelerated hypertension. J Pharmacol Exp Ther. (2002) 301(1):21-28.
168. Barone FC, Campbell WG Jr, Nelson AH, Feuerstein GZ: Carvedilol prevents severe hypertensive cardiomyopathy and remodeling. J Hypertensio. (1998) 16(6):871-884.
169. Barone FC, Coatney RW, Chandra S, Sarkar SK, Nelson AH, Contino LC, Brooks DP, Campbell WG Jr, Ohlstein EH, Willette RN: Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone rats. Cardiovasc Res. (2001) 50(3):525-537.
170. Barone FC, Willette RN, Nelson AH, Ohlstein EH, Brooks DP, Coatney RW: Carvedilol prevents and reverses hypertrophy- induced cardiac dysfunction. Pharmacolog. (2007) 80(2-3):166-176.
171. Kimura S, Saito H, Minami M, Togashi H, Nakamura N, Nemoto M, Parvez HS: Pathogenesis of vascular dementia in stroke-prone spontaneously hypertensive rats. Toxicology. (2000) 153(1-3):167-178. Excellent review of the SP rat as a model of VCI.
172. Kimura S, Saito H, Minami M, Togashi H, Nakamura N, Ueno K, Shimamura K, Nemoto M, Parvez H: Docosahexaenoic acid attenuated hypertension and vascular dementia in stroke-prone spontaneously hypertensive rats. Neurotoxicol Teratol. (2002) 24(5):683-693.
173. Kimura S, Tamayama M, Minami M, Hata N, Saito H: Docosahexaenoic acid inhibits blood viscosity in stroke-prone spontaneously hypertensive rats. Res Commun Mol Pathol Pharmacol. (1998) 100(3):351-361.
174. Watanabe S, Suzuki E, Kojima N, Kojima R, Suzuki Y, Okuyama H: Effect of dietaryα-linolenate/linoleate balance on collagen-induced platelet aggregation and serotonin release in rats. Chem Pharm Bull. (1989) 37(6):1572-1575.
175. Kimura S, Minami M, Hata N, Saito H: Ameliorative effects of docosahexaenoic acid on serum lipid changes in stroke-prone spontaneously hypertensive rats. Res Commun Mol Pathol Pharmacol. (1998) 100(1):53-64.
176. Minami M, Kimura S, Endo T, Hamaue N, Hirafuji M, Togashi H, Matsumoto M, Yoshioka M, Saito H, Watanabe S, Kobayashi T, Okuyama H: Dietary docosahexaenoic acid increases cerebral acetylcholine levels and improves passive avoidance performance in stroke-prone spontaneously hypertensive rats. Pharmacol Biochem Behav. (1997) 58(4):1123-1129.
177. Togashi H, Kimura S, Matsumoto M, Yoshioka M, Minami M, Saito H: Cholinergic changes in the hippocampus of stroke-prone spontaneously hypertensive rats. Stroke. (1996) 27(3):520-526.
178. Yamori Y: Predictive and preventive pathology of cardiovascular diseases. Acta Pathol Jpn. (1989) 39(11):683-705.
179. Wolfson C, Oremus M, Shukla V, Momoli F, Demers L, Perrault A, Moride Y: Donepezil and rivastigmine in the treatment of Alzheimer's disease: A best-evidence synthesis of the published data on their efficacy and cost-effectiveness. Clin Ther. (2002) 24(6):862-886.
180. Meyer JS, Chowdhury MH, Xu G, Li YS, Quach M: Donepezil treatment of vascular dementia. Ann NY Acad Sci. (2002) 977:482-486.
181. Black S, Roman G, Geldmacher DS, Salloway S, Hecker J, Burns A, Perdomo CA, Kumar D, Pratt RD: Efficacy and tolerability of donepezil in vascular dementia: Positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke. (2003) 34(10):2323-2330.
182. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV: Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet. (2002) 359(9314):1283-1290.
183. Baskys A, Hou AC: Vascular dementia: Pharmacological treatment approaches and perspectives. Clin Interv Aging. (2007) 2(3):327-335. Provides a review and clinical trial summary of drugs in VCI.
184. Demaerschalk BM, Wingerchuk DM: Treatment of vascular dementia and vascular cognitive impairment. Neurologis. (2007) 13(1):37-41. Provides a review of ACh esterase inhibitors and NMDA antagonists in VCI.
185. Moretti R, Torre P, Antonello RM, Cazzato G, Griggio S, Ukmar M, Bava A: Rivastigmine superior to aspirin plus nimodipine in subcortical vascular dementia: An open, 16-month, comparative study. Int J Clin Prac. (2004) 58(4):346-353.
186. Wilcock G, Mobius HJ, Stoffler A: A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmaco. (2002) 17(6):297-305.
187. Orgogozo JM, Rigaud AS, Stoffler A, Mobius HJ, Forette F: Efficacy and safety of memantine in patients with mild to moderate vascular dementia: A randomized, placebo-controlled trial (MMM 300). Stroke. (2002) 33(7): 1834-1839.
188. Forette F, Seux ML, Staessen JA, Thijs L, Birkenhager WH, Babarskiene MR, Babeanu S, Bossini A, Gil-Extremera B, Girerd X, Laks T et al. Prevention of dementia in randomised double-blind placebo-controlled systolic hypertension in Europe (Syst-Eur) trial. Lancet. (1998) 352(9137):1347-1351.
189. Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, Bossini A, Fagard R, Gil-Extremera B, Laks T, Kobalava Z et al. The prevention of dementia with antihypertensive treatment: New evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med. (2002) 162(18):2046-2052.
190. Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, Chalmers J, The PROGRESS Collaborative Group: Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med. (2003) 163(9):1069-1075.
191. Murray MD, Lane KA, Gao S, Evans RM, Unverzagt FW, Hall KS, Hendrie H: Preservation of cognitive function with antihypertensive medications: A longitudinal analysis of a community-based sample of African Americans. Arch Intern Med. (2002) 162(18):2090-2096.
192. Peila R, White LR, Masaki K, Petrovitch A, Launer LT: Reducing the risk of dementia: Efficacy of long term treatment of hypertension. Stroke. (2006) 37(5):1165-1170.
193. Iadecola C, Gorelick PB: Hypertension, angiotensin, and stroke: Beyond blood pressure. Stroke. (2004) 35(2):348-350.
194. Coca A: Cerebral involvement in hypertensive cardiovascular disease. Eur Heart. (2003) 5(Suppl F):F19-F25. Review of anti-hypertensive drugs in development and treatment of VCI and dementia.
195. Walters RJL, Fox NC, Schott JM, Crum WR, Stevens JM, Rossor MN, Thomas DJ: Transient ischaemic attacks are associated with increased rates of global cerebral atrophy. J Neurol Neurosurg Psychiatry. (2003) 74(2):213-216.
196. Shaw LM, Korecka M, Clark CM, Lee VM, Trojanowski JQ: Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov.. (2007) 6(4):295-303.
197. Racchi M, Uberti D, Govoni S, Memo M, Lanni C, Vasto S, Candore G, Caruso C, Romeo L, Scapagnini G: Alzheimer's disease: New diagnostic and therapeutic tools. Immun Aging. (2008) 5:7.
198. Gurol ME, Irizarry MC, Smith EE, Raju S, Diaz-Arrastia R, Bottiglieri T, Rosand J, Growdon JH, Greenberg SM: Plasmaβ-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology. (2006) 66(1):23-29.
199. Zhou Y, Dougherty JH Jr, Hubner KF, Bai B, Cannon RL, Hutson RK: Abnormal connectivity in the posterior cingulate and hippocampus in early Alzheimer's disease and mild cognitive impairment. Alzheimers Dement. (2008) 4(4):265-270.
200. Hall AM, Moore RY, Lopez OL, Kuller L, Becker JT:Basal forebrain atrophy is a presymptomatic marker for Alzheimer's disease. Alzheimers Dement. (2008) 4(4):265-270.
201. Brickman AM, Honig LS, Scarmeas N, Tatarina O, Sanders L, Albert MS, Brandt J, Blacker D, Stern Y: Measuring cerebral atrophy and white matter hyperintensity burden to predict the rate of cognitive decline in Alzheimer disease. Arch Neurol. (2008) 65(9):1202-1208.
202. Kawarabayashi T, Shoji M: Plasma biomarkers of Alzheimer's disease. Curr Opin Psychiatry. (2008) 21(3):260-267.
203. Crystal HA, Dickson DW, Sliwinski MJ, Lipton RB, Grober E, Marks-Nelson H, Antis P: Pathological markers associated with normal aging and dementia in the elderly. Ann Neurol. (1993) 34(4):566-573.